TY  - JOUR
T1  - Parkinson's Disease, Therapy with Drugs and Nanotechnology
AU  - Küçükoğlu, Kaan
AU  - Nadaroglu, Hayrunnisa
PY  - 2022
DA  - December
JF  - International Journal of Innovative Research and Reviews
JO  - INJIRR
PB  - Muhammet Kaan YEŞİLYURT
WT  - DergiPark
SN  - 2636-8919
SP  - 121
EP  - 131
VL  - 6
IS  - 2
LA  - en
AB  - Parkinson's disease (PD) is a disorder that destroys neurons in the extrapyramidal dopaminergic pathway in the brain. In the world, the number of patients with PD is 10 million now and PD is a disease whose incidence increases with age. In particular, genetic and environmental factors are believed to cause PD. Rigidity in striated muscles, characteristic tremors and posture disorder are specified as main clinical symptoms of PD. Although radical treatment of PD is not possible today, some drugs that slow the progression of it and effective on its symptoms are used successfully in the clinic. Among them, the essential drug is levodopa. However, an important disadvantage in the drug treatment of PD is that the beneficial effects of the drugs decrease over time in long-term use. Moreover, the use of them is associated with serious side effects. Therefore, it is important to develop new treatment strategies in the treatment of PD. When a great effort continues to discover new drugs having different action mechanisms, it is expected that developed nanotechnology-based drugs for PD therapy become important, additionally.
KW  - Parkinson
KW  - Symptoms
KW  - Therapy
KW  - Drug
KW  - Nanotechnology
KW  - Nanomedicine
UR  - https://dergipark.org.tr/en/pub/injirr/article/1218962
L1  - https://dergipark.org.tr/en/download/article-file/2831548
ER  -